Corline Biomedical AB (CLBIO) AI Stock Analysis

0 Followers

Corline Biomedical AB

(Nasdaq OMX AB:CLBIO)

Select Model

Rating:49Neutral

Price Target:SEK 13.00▼(-5.80% Downside)

Action:reiterated

Date:08/27/26

The score is primarily held back by weak financial performance (ongoing losses and cash burn) despite a strong, low-risk balance sheet with zero debt. Technicals also lean bearish with the stock trading below major moving averages and subdued momentum. Valuation provides limited support due to a negative P/E and no dividend yield data.

Positive Factors

Debt-free balance sheetZero debt removes leverage pressure and gives Corline greater financial flexibility than a debt-funded business. Its sizable equity base relative to assets also provides resilience, allowing management more room to fund development and partnerships without immediate refinancing constraints.

Negative Factors

Persistent operating lossesCorline remains deeply loss-making despite revenue growth, showing that current scale and pricing do not yet cover the cost base. Persistent negative margins reduce internal funding capacity and make improved execution, commercial conversion, and cost discipline important to the business outlook.

Corline Biomedical AB (CLBIO) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 360.64M
Dividend Yield: ―
Average Volume (3M): 13.79K
Price to Earnings (P/E): -28.0
Beta (1Y): 0.41
Revenue Growth: 54.37%
EPS Growth: 52.22%
Country: Sweden
Employees: 14
Sector: General
Sector Strength: 55
Industry: Biotechnology

Corline Biomedical AB Business Overview & Revenue Model

Company Description

Corline Biomedical AB is a company dedicated to the creation, production, and distribution of heparin-based solutions. These solutions are specifically engineered to enhance outcomes in kidney transplantation, cellular therapies, and regenerative med...

How the Company Makes Money

Corline Biomedical makes money primarily by commercializing its blood-compatible biomaterial and surface-technology solutions through product sales and B2B collaborations. Key revenue streams typically include: (1) Sales of proprietary products/consu...

Corline Biomedical AB Financial Statement Overview

Summary

Balance sheet strength (zero debt, solid equity base) supports financial resilience, but this is offset by weak profitability and deteriorating cash generation: the company is deeply loss-making TTM with negative operating/net margins and meaningful operating/free-cash-flow burn.

Income Statement

28Negative

Balance Sheet

74Positive

Cash Flow

33Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	12.39M	7.65M	9.78M	25.03M	23.55M	7.06M
Gross Profit	4.87M	-14.21M	13.44M	28.38M	22.73M	9.10M
EBITDA	-12.23M	-14.12M	-23.07M	-1.69M	2.38M	-6.88M
Net Income	-12.32M	-14.71M	-23.19M	-1.81M	2.33M	-6.92M
Balance Sheet
Total Assets	114.18M	98.58M	94.76M	100.11M	101.78M	101.66M
Cash, Cash Equivalents and Short-Term Investments	32.99M	20.56M	17.67M	17.01M	26.21M	41.63M
Total Debt	0	0	0	0	0	0
Total Liabilities	15.18M	4.82M	7.85M	6.79M	7.19M	9.43M
Stockholders Equity	99.00M	93.76M	86.91M	93.32M	94.59M	92.23M
Cash Flow
Free Cash Flow	-14.85M	-17.74M	-16.14M	-9.73M	-15.45M	-14.45M
Operating Cash Flow	-14.44M	-17.69M	-8.64M	886.00K	-6.45M	-4.83M
Investing Cash Flow	-750.00K	-982.00K	-7.50M	-10.62M	-9.00M	-9.56M
Financing Cash Flow	39.87M	21.56M	16.79M	537.00K	26.00K	47.13M

Corline Biomedical AB Technical Analysis

Technical Analysis SentimentNeutral

Last Price13.80

Price Trends

50DMA14.33Negative

100DMA15.97Negative

200DMA16.28Negative

Market Momentum

MACD-0.35Positive

RSI49.50Neutral

STOCH71.63Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CLBIO, the sentiment is Neutral. The current price of 13.80 is above the 20-day moving average (MA) of 13.72, below the 50-day MA of 14.33, and below the 200-day MA of 16.28, indicating a neutral trend. The MACD of -0.35 indicates Positive momentum. The RSI at 49.50 is Neutral, neither overbought nor oversold. The STOCH value of 71.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:CLBIO.

Corline Biomedical AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

SE:CLBIO against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
SE:HNSA	50Neutral	SEK 3.96B	-5.69	―	―	-3.57%	8.84%
SE:CLBIO	49Neutral	SEK 337.12M	-28.02	―	―	54.37%	52.22%
SE:NXTCL	46Neutral	SEK 32.36M	-0.65	-81.23%	―	-4.02%	35.86%
SE:SPAGO	43Neutral	SEK 34.97M	-1.17	-87.37%	―	-97.52%	31.31%
SE:FLUO	40Underperform	SEK 480.67M	-6.51	―	―	―	-23.57%

* General Sector Average

Performance Comparison

SE:CLBIO and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:CLBIO	Corline Biomedical AB	13.80	-4.65	-25.20%
SE:HNSA	Hansa Biopharma	44.76	17.80	66.02%
SE:NXTCL	NextCell Pharma AB	0.25	-0.55	-68.88%
SE:SPAGO	Spago Nanomedical AB	0.05	-0.07	-59.29%
SE:BIOWKS	Bio-Works Technologies AB	3.02	0.27	9.82%
SE:FLUO	FluoGuide A/S	28.90	-14.80	-33.87%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 27, 2026

Corline Biomedical AB AI Stock Analysis